company background image
41O logo

Outlook Therapeutics DB:41O Stock Report

Last Price

€7.72

Market Cap

€169.6m

7D

33.1%

1Y

-58.0%

Updated

26 Mar, 2024

Data

Company Financials +

Outlook Therapeutics, Inc.

DB:41O Stock Report

Market Cap: €169.6m

41O Stock Overview

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.

41O fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Outlook Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Outlook Therapeutics
Historical stock prices
Current Share PriceUS$7.72
52 Week HighUS$36.80
52 Week LowUS$3.58
Beta-0.0025
1 Month Change0%
3 Month Change0.52%
1 Year Change-57.99%
3 Year Change-77.69%
5 Year Changen/a
Change since IPO-85.15%

Recent News & Updates

Recent updates

Shareholder Returns

41ODE BiotechsDE Market
7D33.1%3.3%1.6%
1Y-58.0%35.8%6.4%

Return vs Industry: 41O underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: 41O underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is 41O's price volatile compared to industry and market?
41O volatility
41O Average Weekly Movement16.9%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 41O has not had significant price volatility in the past 3 months.

Volatility Over Time: 41O's weekly volatility has decreased from 23% to 17% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201024Russ Trenaryhttps://www.outlooktherapeutics.com

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte.

Outlook Therapeutics, Inc. Fundamentals Summary

How do Outlook Therapeutics's earnings and revenue compare to its market cap?
41O fundamental statistics
Market cap€169.59m
Earnings (TTM)-€47.55m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
41O income statement (TTM)
RevenueUS$0
Cost of RevenueUS$21.12m
Gross Profit-US$21.12m
Other ExpensesUS$30.38m
Earnings-US$51.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.39
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-150.1%

How did 41O perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.